Company Overview
| Stock Name | Broncus-B |
|---|---|
| Stock Code | 02216 |
| Company Full Name | To be extracted |
| Industry | Healthcare |
| Principal Activities | 專注於介入呼吸病學產品開發的醫療器械公司,利用專有全肺抵達導航技術,開發包括導航、診療的綜合介入呼吸病學平台,提供創新型肺部疾病解決方案,核心產品包括InterVapor熱蒸汽能量消融系統及RF-II射頻消融系統。 |
| Listing Date | 2021-09-24 |
| Listing Rules Era | Old Rules |
| Listing Rules Chapter | 18A生物科技 |
| Weighted Voting Rights (WVR) | No |
| Registered Address (Mainland China) | 杭州市濱江區西興街道江陵路88號8幢8層801室 |
| Business Address (Hong Kong) | 香港灣仔皇后大道東248號大新金融中心40樓 |
| Place of Incorporation | To be extracted |
| Listing Method | To be extracted |
| Listing Board | Main Board |
| Website | www.broncus.com |
| Share Registrar | 香港中央證券登記有限公司 (Computershare Hong Kong Investor Services Limited) |
| Registrar Contact | (852)2862 8628 |
| A-Share/US Dual Listing | No |
Offering Information
| Offering Mechanism | 18A生物科技 |
|---|---|
| Offer Price | HK$ 18.70 / shares |
| Offer Price Range | Final offer price only, no range |
| Lot Size | 500 shares |
| Entry Threshold | HK$ 9,350 |
| Par Value | To be extracted |
| Offer Period | 2021-09-13 to 2021-09-16 |
| Global Offering Shares | 89,355,000 shares |
| HK Public Offer Shares (Initial) | 8,935,500 shares (10.0%) |
| Public Offer Lots (Initial) | 17,871lots (Pool A8,935lots,Pool B8,936lots) |
| International Placing Shares (Initial) | 80,419,500 shares (90.0%) |
| Offer Ratio | ~10.0% |
| Total Shares Post-IPO | 525,616,784 shares |
| Greenshoe (Over-allotment Option) | Yes |
| Stabilizing Manager (Greenshoe) | To be extracted |
| Cornerstone Share | 42.4% |
| Clawback Tiers | To be extracted |
| Reallocation Option | No |
| Total Global Offering Size | HK$ 1,670,938,500 |
Subscription Tiers
Minimum subscription unit: 1 lot. Subscription amount ≤ HK$5,000,000 is Pool A, > HK$5,000,000 is Pool B.
Pool A
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 1 lots | 500 | HK$ 9,350 |
| 2 lots | 1,000 | HK$ 18,700 |
| 3 lots | 1,500 | HK$ 28,050 |
| 4 lots | 2,000 | HK$ 37,400 |
| 5 lots | 2,500 | HK$ 46,750 |
| 6 lots | 3,000 | HK$ 56,100 |
| 7 lots | 3,500 | HK$ 65,450 |
| 8 lots | 4,000 | HK$ 74,800 |
| 9 lots | 4,500 | HK$ 84,150 |
| 10 lots | 5,000 | HK$ 93,500 |
| 12 lots | 6,000 | HK$ 112,200 |
| 14 lots | 7,000 | HK$ 130,900 |
| 16 lots | 8,000 | HK$ 149,600 |
| 18 lots | 9,000 | HK$ 168,300 |
| 20 lots | 10,000 | HK$ 187,000 |
| 30 lots | 15,000 | HK$ 280,500 |
| 40 lots | 20,000 | HK$ 374,000 |
| 50 lots | 25,000 | HK$ 467,500 |
| 60 lots | 30,000 | HK$ 561,000 |
| 70 lots | 35,000 | HK$ 654,500 |
| 80 lots | 40,000 | HK$ 748,000 |
| 90 lots | 45,000 | HK$ 841,500 |
| 100 lots | 50,000 | HK$ 935,000 |
| 120 lots | 60,000 | HK$ 1,122,000 |
| 140 lots | 70,000 | HK$ 1,309,000 |
| 160 lots | 80,000 | HK$ 1,496,000 |
| 180 lots | 90,000 | HK$ 1,683,000 |
| 200 lots | 100,000 | HK$ 1,870,000 |
| 400 lots | 200,000 | HK$ 3,740,000 |
Pool B
| Lots Subscribed | Shares Subscribed | Subscription Amount (HKD) |
|---|---|---|
| 600 lots | 300,000 | HK$ 5,610,000 |
| 800 lots | 400,000 | HK$ 7,480,000 |
| 1,000 lots | 500,000 | HK$ 9,350,000 |
| 1,200 lots | 600,000 | HK$ 11,220,000 |
| 1,600 lots | 800,000 | HK$ 14,960,000 |
| 2,000 lots | 1,000,000 | HK$ 18,700,000 |
| 3,000 lots | 1,500,000 | HK$ 28,050,000 |
| 4,000 lots | 2,000,000 | HK$ 37,400,000 |
| 8,935 lots | 4,467,500 | HK$ 83,542,250 |
Stock Connect Inclusion Analysis
| 26Q4 Regular Review | |
| Inclusion Pathway | Regular Path |
|---|---|
| Avg Daily HK Mkt Cap | HK$ 519.1M |
| Est. Threshold | HK$ 9.69B |
| Analysis Result | HK market cap below threshold, need +1767% |
Valuation & Financials
| Market Cap (at Offer Price) | HK$ 9,829,033,860 |
|---|---|
| Pre-IPO Valuation (Last Round) | Not disclosed |
| P/E Ratio | 不適用(公司處於虧損狀態) |
| Profit/Loss Status | 虧損48.8百萬美元 |
| Period-End Cash Balance | To be extracted |
| Listing Expenses | To be extracted |
| Listing Expenses / Funds Raised | To be extracted |
| Total Pre-IPO Investment | To be extracted |
Financial Data
Unit:
'000
USD
Income Statement
| Item | 2019 | 2020 |
|---|---|---|
| Revenue | 8,072 | 3,260 |
| Cost of sales | -2,094 | -754 |
| Gross profit | 5,980 | 2,506 |
| Other income and gains, net | 305 | 1,074 |
| Selling and distribution expenses | -8,609 | -6,352 |
| Administrative expenses | -8,855 | -7,742 |
| Net finance costs | -518 | -648 |
| Profit before tax | -32,450 | -48,484 |
| Income tax expense | -2 | -2 |
| Profit for the year | -32,351 | -48,386 |
| Profit attributable to owners | -31,939 | -48,237 |
Balance Sheet
| Item | 2019 | 2020 | 2021-04 |
|---|---|---|---|
| Cash and cash equivalents | 3,085 | 18,768 | |
| Trade and bills receivables | 3,189 | 2,936 | |
| Inventories | 1,828 | 3,031 | |
| Total current assets | 9,056 | 26,702 | |
| Total assets | 22,003 | 39,887 | |
| Total current liabilities | 14,144 | 14,247 | |
| Total liabilities | 95,882 | 163,338 | |
| Total equity | -73,878 | -124,451 | |
| Equity attributable to owners | -72,364 | -121,523 | |
| Interest-bearing borrowings | 5,772 | 4,188 | 799 |
Cash Flow Statement
| Item | 2019 | 2020 | 2021-04 |
|---|---|---|---|
| Net cash from operating activities | -15,800 | ||
| Depreciation of PP&E | 248 | 287 | 216 |
| Depreciation of right-of-use assets | 576 | 658 | 212 |
| Amortisation of intangible assets | 1,249 | 1,247 | 417 |
| Purchase of PP&E | -361 | -1,101 | -1,187 |
Income Statement
Balance Sheet
Cash Flow Statement
Source: Accountants' Report and Audited Consolidated Financial Statements
| First Day Close | HK$ 15.0 |
|---|---|
| First Day Open | HK$ 18.0 |
| First Day Change | -19.79% |
| First Day Volume | 19821500.0 |
| First Day Turnover | 318630000.0 |
| Use of Proceeds | 1、49.9%(或約774.8百萬港元)分配予我們的核心產品;
2、18.5%(或約287.4百萬港元)分配予我們的其他產品及候選產品;
3、9.2%(或約143.0百萬港元)將用于為繼續擴大我們生產廠房的生產線提供資金;
4、13.2%(或約204.3百萬港元)將用于為通過潛在收購持續擴大產品組合提供資金;
5、9.2%(或約143.0百萬港元)將用于營運資金及其他一般公司用途。 |
Underwriting Syndicate
Overall Coordinators (3)
Joint Bookrunners (7)
Joint Lead Managers (7)
Cornerstone Investors
| # | Investor Name | Investment Amount | Shares Subscribed | % of Offer Shares | % of Total Shares | Lock-up Period | Est. Unlock Date |
|---|---|---|---|---|---|---|---|
| 1 | Artisan China Post-Venture Master Fund LP | 38,858,600 HKD | — | 2.30% | — | 6 months | 2022-03-24 |
| 2 | Cephei | 77,717,200 HKD | — | 4.70% | — | 6 months | 2022-03-24 |
| 3 | Emerging Markets Healthcare Partners LLC | 15,539,700 HKD | — | 0.90% | — | 6 months | 2022-03-24 |
| 4 | Lake Bleu Prime Healthcare Master Fund Limited | 155,434,400 HKD | — | 9.30% | — | 6 months | 2022-03-24 |
| 5 | Snow Lake China Master Fund, Ltd. | 77,717,200 HKD | — | 4.70% | — | 6 months | 2022-03-24 |
| 6 | Springhill Master Fund Limited | 38,858,600 HKD | — | 2.30% | — | 6 months | 2022-03-24 |
| 7 | Summer Healthcare Fund, L.P. | 77,717,200 HKD | — | 4.70% | — | 6 months | 2022-03-24 |
| 8 | The Valliance Fund | 23,309,550 HKD | — | 1.40% | — | 6 months | 2022-03-24 |
| 9 | UBS Asset Management (Singapore) Ltd. | 194,293,000 HKD | — | 11.60% | — | 6 months | 2022-03-24 |
| 10 | Worldwide Healthcare Partners LLC | 7,769,850 HKD | — | 0.50% | — | 6 months | 2022-03-24 |
Directors & Management
| Position | Chinese name | English Name |
|---|---|---|
| Chairman | 趙亦偉 | — |
| Company Secretary | 王文豪、劉准羽 | — |
No director data available.
Major Shareholders
| Major Shareholders & Holdings | 控股股東QM12及BBL一致行動,連同訾先生及其他股東合共持有上市前50.41%權益,緊隨全球發售完成後約38.06%。其中訾先生持有29.89%(上市前)及22.57%(上市後),QM12持有20.52%及15.49%,BBL持有11.03%及8.32%。 |
|---|




